The mission of TregTherapeutics, Inc is to provide resources to expedite development, and ultimately, the availability of next-generation therapeutics for the treatment of autoimmune and neurodegenerative disease.
The technology has potential application in a range of disease states that share inflammation as a common denominator. The approach defined by our platform technology is applicable to dozens of autoimmune diseases, as well as, numerous neurodegenerative diseases, but the roots of the technology are deeply embedded in the treatment and potential cure of multiple sclerosis. The company’s strategic plan recognizes that financial, technical, and time resources need to be focused, and management has developed a tactical plan to bring the technology into the clinic smoothly and quickly. That particular pathway can be discussed upon inquiry.
TregTherapeutics’ technical objectives, then, are clear. Human proof of concept studies have been formulated for a representative autoimmune disease and for a selected neurodegenerative disease. Resources are being assembled to proceed with first-in-human studies of both.
Financial resources are critical to the success of the enterprise. Availability of funding has an impact on our ability to proceed with planned activities, and acquiring the resources to enable execution of the chosen pathway is our highest priority. We are currently pursuing equity funding and are interested in establishing relationships with individual investors, venture capital firms, or appropriate pharmaceutical / biotech companies. Interested investors are urged to contact us for further information.